A monitoring team from the Menzies School of Health Research recently evaluated the ongoing "A Revised Tafenoquine Dose to Improve Radical Cure for Vivax Malaria" (TADORE) study at Arba Minch General Hospital. This project is a collaborative initiative involving the College of Medicine and Health Sciences at Arba Minch University, the Menzies School of Health Research in Australia, and Arba Minch General Hospital, formalized through an agreement signed in September 2024.Click here to see more photos
Dr. Zerihun Zerdo, Research Director of the College of Medicine and Health Sciences at Arba Minch University, highlighted the importance of collaborative research. "Collaborative efforts like the TADORE study are crucial for tackling complex health issues such as Vivax Malaria. Our college is dedicated to supporting these initiatives by providing the necessary resources and expertise to ensure their success. Additionally, as Arba Minch University strives to become a research-led autonomous institution, such collaborations are vital for strengthening our research capacity, expanding global partnerships, and establishing ourselves as leaders in health research."
Dr. Tamiru Shibiru, the Principal Investigator of the project, stated that following the signing of the agreement, the research required approval from the Ethiopian Food and Drug Authority. Once this approval was obtained, patient enrollment for the clinical trial commenced on December 20, 2024, and 30 patients have been enrolled so far. The study is designed to be conducted across four countries: Ethiopia, Brazil, Indonesia, and Papua New Guinea. The team in Brazil has already initiated their work and has enrolled 80 patients to date.
Dr. Tamiru emphasized the importance of monitoring in ensuring the integrity and reliability of clinical trial data. "The TADORE study aims to refine Tafenoquine dosing for a more effective radical cure of Vivax Malaria, a major public health concern," Dr. Tamiru explained. "Given that this is a clinical trial, it requires meticulous attention and thorough care. Rigorous monitoring by our Menzies partners ensures strict adherence to the highest standards, which is crucial for the safety of patients, integrity of the data and the success of the trial, ultimately leading to improved treatment outcomes for patients."
According to Dr. Tamiru, the three-year study focuses on Vivax Malaria, which can persist in the liver and cause recurring infections. The goal is to identify more effective treatments and develop faster-acting cures.
The monitoring team, led by Clinical Research Expert Hellen Mnjala and Clinical Trial Data Manager Grant Lee, reviewed the study’s data accuracy, participant safety, and adherence to protocols, regulatory standards, and ethical guidelines.
Hellen Mnjala, Clinical Research Coordinator, shared insights on malaria research at sites in Brazil, Indonesia, Papua New Guinea, and Ethiopia, all of which comply with local requirements and undergo rigorous monitoring. This research is expected to advance healthcare practices and modernize malaria treatment options, benefiting communities and improving health outcomes.
Grant Lee in his part highlighted his team’s role in ensuring high-quality data collection throughout the trial. He noted that his presence in Arba Minch is dedicated to supporting quality data collection, ensuring effective patient safety.
The study’s impact is highlighted by the involvement of 450 patients, a 6-month follow-up, and a team of 14 research experts. With $377,002 USD in funding, this collaboration is a crucial step in advancing malaria treatment and improving patient care in the region.
Arba Minch University
The Center of Bright Future!
For more Information Follow us on:-
Website - https://www.amu.edu.et/
Telegram - https://t.me/arbaminch_university
Facebook - https://www.facebook.com/ArbaMinchUniversityccd/
YouTube - https://www.youtube.com/channel/UCOO_nclhMo8M3r74OyPBlVA
Public and International Relations Executive